Semaglutide and the GLP-1 Receptor Agonist Class

GLP-1 receptor agonists are synthetic peptides or small molecules that bind to and activate the GLP-1 receptor, a G-protein coupled receptor found primarily in pancreatic islet cells, the gastrointestinal tract, and the central nervous system. The class was developed to harness the glucose-lowering and incretin-mimetic effects of native GLP-1 while overcoming its rapid enzymatic degradation. The first approved GLP-1 agonist, exenatide, entered clinical practice in 2005; the class has since expanded to include multiple agents with varying pharmacokinetic profiles and clinical indications.

Clinically approved GLP-1 agonists in major markets include exenatide, liraglutide, dulaglutide, semaglutide, and tirzepatide (the latter a dual GIP/GLP-1 agonist). Each differs in peptide structure, half-life, route of administration, frequency of dosing, and approved indications. Semaglutide's extended half-life and dual approval for both type 2 diabetes and chronic weight management position it as a particularly versatile member of the class.

All GLP-1 receptor agonists function through a common mechanism: agonism of the GLP-1 receptor. This binding activates adenylyl cyclase, increasing intracellular cAMP and triggering downstream signaling cascades that promote glucose-dependent insulin secretion, suppress glucagon release, slow gastric emptying, and reduce appetite. The shared mechanism explains consistent efficacy across the class in reducing fasting and postprandial glucose levels and inducing modest weight loss.

Despite this shared primary mechanism, individual members of the class exhibit different potencies at the GLP-1 receptor, different pharmacokinetic profiles, and potentially different tissue-specific effects. These variations arise from differences in peptide structure, albumin binding, receptor selectivity, and distribution across target tissues. Understanding these nuances is important for evaluating efficacy, safety profiles, and clinical applicability of different GLP-1 agonists.

Exenatide (Byetta) has a half-life of 2.5 hours and is administered twice daily via subcutaneous injection. Liraglutide (Victoza, Saxenda) has a half-life of 13 hours and is dosed once daily. Dulaglutide (Trulicity) has a half-life of 4–5 days and is dosed once weekly. Semaglutide has the longest half-life (~7 days) and is also dosed once weekly, matching dulaglutide's frequency but with superior half-life characteristics. This progression reflects a class-wide trend toward longer-acting, less-frequent dosing to improve adherence.

The extended half-life of semaglutide provides pharmacokinetic advantages: steady-state is achieved in 4–5 weeks (versus weeks for shorter-acting agents), and the risk of missing a single weekly dose is mitigated by the long drug half-life. This characteristic may translate to better real-world adherence and more consistent glycaemic control compared to agents requiring more frequent dosing. However, longer half-lives also mean slower onset of action and slower clearance if adverse effects occur.

While all GLP-1 agonists share a common mechanism, clinical trials demonstrate variable efficacy in glycaemic control and weight loss. In type 2 diabetes trials, HbA1c reductions range from approximately 0.5% (exenatide) to 1.5% (semaglutide and dulaglutide). Weight loss varies more dramatically: exenatide and liraglutide typically produce 2–4 kg weight loss, while semaglutide in type 2 diabetes trials achieved approximately 4–6 kg weight loss, with even greater losses (up to 15% baseline weight) in dedicated obesity trials. These differences may reflect variations in potency, tissue selectivity, dose-escalation schedules, and trial populations.

The reasons for superior weight loss with semaglutide remain incompletely understood but likely involve its extended half-life, achieving more sustained receptor occupancy, and potentially greater penetration across the blood–brain barrier relative to other agonists. Preclinical data suggest semaglutide may have higher intrinsic activity at the GLP-1 receptor compared to some competitors, though direct head-to-head clinical comparisons are limited.

The GLP-1 receptor agonist class demonstrates cardioprotective effects beyond glycaemic control. The LEADER trial (liraglutide) and SUSTAIN-6 trial (semaglutide) both demonstrated reductions in cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke in patients with type 2 diabetes and established cardiovascular disease. These benefits appear to be class effects, observed across multiple GLP-1 agonists, though the magnitude and mechanisms may differ. Emerging data from the SELECT trial (semaglutide in obesity without diabetes) suggest cardiovascular benefits extend to obese patients without diabetes.

Regarding renal outcomes, GLP-1 agonists have shown benefits in slowing diabetic nephropathy progression and reducing albuminuria in patients with type 2 diabetes. These renal protective effects appear mediated by improved glycaemic control, blood pressure reduction, and potentially direct effects on glomerular filtration and tubular function. However, direct renal outcome trials comparing different GLP-1 agonists are limited, and the comparative renal benefits remain incompletely characterized.

Despite two decades of GLP-1 agonist development, several mechanistic questions remain unresolved. The relative contributions of central versus peripheral GLP-1 receptor signaling to weight loss and cardiovascular benefits are not fully delineated in humans. Additionally, the class demonstrates variable tolerability across individuals; some patients experience gastrointestinal side effects that limit dose titration or prompt discontinuation. The biological basis for this individual variation is poorly understood. Finally, whether all GLP-1 agonists share equivalent cardiovascular and renal benefits, or whether differences exist based on structure and pharmacology, requires further investigation through comparative effectiveness trials.

Long-term safety and efficacy beyond 2–3 years of treatment remain incompletely characterized for the entire class. The class black-box warning regarding thyroid C-cell tumours, derived from rodent studies, has not translated to clinical thyroid cancer risk in humans, but mechanistic understanding of species-specific toxicology remains incomplete. These gaps highlight the importance of ongoing real-world evidence collection and comparative research across the GLP-1 agonist class.